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Background: Atherosclerosis is considered a progressive disease that affects arteries that bring blood to the heart, to
the brain and to the lower end. It derives from endothelial dysfunction and inflammation, which play an important role
in the thrombotic complications of atherosclerosis. Cardiovascular disease is the leading cause of death around the
world and one factor that can contribute to its progression and prevention is diet. Our previous study found that
amaranth hydrolysates inhibited LPS-induced inflammation in human and mouse macrophages by preventing activation
of NF-κB signaling. Furthermore, extrusion improved the anti-inflammatory effect of amaranth protein hydrolysates in
both cell lines, probably attributed to the production of bioactive peptides during processing. Therefore, the objective of
this study was to compare the anti-atherosclerotic potential of pepsin-pancreatin hydrolysates from unprocessed and
extruded amaranth in THP-1 lipopolysaccharide-induced human macrophages and suggest the mechanism of action.
Results: Unprocessed amaranth hydrolysate (UAH) and extruded amaranth hydrolysate (EAH) showed a significant
reduction in the expression of interleukin-4 (IL-4) (69% and 100%, respectively), interleukin-6 (IL-6) (64% and 52%,
respectively), interleukin-22 (IL-22) (55% and 70%, respectively). Likewise, UAH and EAH showed a reduction in
the expression of monocyte-chemo attractant protein-1 (MCP-1) (35% and 42%, respectively), transferrin
receptor-1 (TfR-1) (48% and 61%, respectively), granulocyte-macrophage colony-stimulating factor (GM-CSF)
(59% and 63%, respectively), and tumor necrosis factor-α (TNF-α) (60% and 63%, respectively). Also, EAH reduced
the expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) (27%), intracellular adhesion
molecule-1 (ICAM-1) (28%) and matrix metalloproteinase-9 (MMP-9) (19%), important molecular markers in the
atherosclerosis pathway. EAH, led to a reduction of 58, 52 and 79% for LOX-1, ICAM-1 and MMP-9, respectively,
by confocal microscopy.
Conclusions: Extruded amaranth hydrolysate showed potential anti-atherosclerotic effect in LPS-induced THP-1
human macrophage-like cells by reducing the expression of proteins associated with LOX-1 signaling pathway.
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Cardiovascular disease (CVD) is the principal cause of
death around the world, including coronary heart dis-
ease, rheumatic heart disease, heart failure, hypertension,
hyperlipidemia, congenital heart disease, and atheroscler-
osis [1]. There is a strong relationship between CVD and
the diet [2]. The consumption of whole cereals, fruits and
vegetables could help to reduce the risk to develop dis-
eases such as obesity, diabetes, hypertension, which are
related with the development of CVD, specifically ath-
erosclerosis [3]. Atherosclerosis is considered as a pro-
gressive disease derived from endothelial dysfunction and
inflammation, with the progressive occlusion of the arter-
ies by a plaque, which consist of cholesterol, aggregating
proteins, calcium and other substances [4-7]. Also, athero-
sclerosis was regarded as a bland lipid storage disease, but
nowadays, it is known that it also involves an ongoing
inflammatory response [8]. Chronic inflammation is in-
volved in the initiation and progression of atherosclerosis,
and plays an important role in thrombotic complications
[3,9,10]. A rupture of the plaque results in the total occlu-
sion of the artery, leading to obstruction of blood flow;
hence a heart attack occurs [11]. Atherosclerosis mainly
affects the arteries that bring blood to the heart (coronar-
ies), to the brain (carotid, cerebral and vertebral) and to
the lower end (iliac and femoral) [12]. When an erosion,
fissure or rupture of the plaque occurs, it leads to the
thrombus formation, causing complications such as cere-
brovascular disease, heart disease or peripheral arterial
disease [13].
Diet is strongly related with initiation and progres-
sion of CVD, since an increment in the calories intake
(diet rich in cholesterol and saturated fat) can elevate
the serum level of low-density lipoproteins (LDLs) [6,10].
When the LDLs are oxidized in the sub-endothelial envir-
onment, by different factors such as free radicals, it is the
triggering step to the atherogenic process [10]. Oxidized
LDL (ox-LDL) plays an important role in the atheroscler-
otic process. When ox-LDL binds to its principal receptor,
lectin-like oxidized low-density lipoprotein receptor 1
(LOX-1), leads to the expression of adhesion molecules
such as intracellular adhesion molecule (ICAM), which
is responsible for the monocytes adhesion to the endo-
thelium [9,10,12,14-16]. Once the monocytes are in the
endothelium, they migrate to the intima (an inner layer
of the artery), due to the action of the monocyte chemo-
attractant protein-1 (MCP-1) [10]. The interaction of
ox-LDL and its receptor, leads to an increase of reactive
oxygen species (ROS) and an increment on the activity of
matrix metalloproteinase (MMP) [4]. Overexpression of
MMP is related with some chronic diseases such as in-
flammation and atherosclerosis [17] and the increase
of ROS inactivates the endothelium nitric oxide syn-
thase (eNOS) [5]. All these steps result in the plaquedestabilization and rupture, leading to thrombus for-
mation [4].
Amaranth (Amaranthus hypochondriacus), a pseudocer-
eal, is an option as a source of proteins that produce bio-
active peptides that prevent chronic diseases. The protein
content of amaranth is higher (13-19%) than most cereals
[18]. It also has bioactive compounds, with health promo-
tion and prevention of CVD and hypercholesterolemia
[18,19]. Peptides derived from unprocessed amaranth have
antioxidant capacity [20]; antihypertensive, anticarcino-
genic and antidiabetic potential [21,22]. Bioactive peptides
from whole cereal grains could prevent CVD [23].
Extrusion, a high temperature–short time technology, has
been used to obtain pre-cooked flours with high nutritional
value [24], antioxidant capacity and anti-inflammatory activ-
ity [25,26]. Montoya-Rodríguez et al. [26] reported, in ex-
truded amaranth flour, peptides with active sequences and
potential antithrombotic activity. However, no studies have
been reported on the effect of extrusion on the anti-
atherosclerotic potential of amaranth hydrolysates in
human macrophages. Therefore, the aim of this study
was to compare the anti-atherosclerotic potential of pepsin-
pancreatin hydrolysates from unprocessed (UAH) and
extruded amaranth (EAH) in THP-1 lipopolysaccharide
(LPS)-induced human macrophages and suggest the
mechanism of action.
Results
Unprocessed and extruded amaranth hydrolysates
showed a reduction in the expression of protein markers
including interleukins involved in atherosclerosis
Figure 1 presents the main peptides found in UAH and
EAH including their amino acid sequence and structure,
molecular mass, net charge, isoelectric point and hydro-
phobicity. Table 1 presents some of the proteins involved
in the atherosclerosis pathway and the percent reduction
found after treatment with UAH and EAH. Table 1 also
includes the role of these proteins in the cell. This table
highlights the high and significant reduction by both
protein hydrolysates on TGF-α which is associated with
atherosclerosis; also on IL-4, associated with the secre-
tion of TGF-β; and also on the reduction of IL-32α/β/γ,
a cytokine that activates NF-κB.
Figure 2 shows the comparative effect of UAH and EAH
on the expression of interleukins, such as IL-4, IL-6, IL-22
and IL-12p70 related with inflammation and atherosclerosis.
UAH and EAH showed a significant (p < 0.05) reduction of
69% and 100% for IL-4; 64% and 52% for IL-6; 55% and 70%
for IL-22; 100% and 51% for IL-12p70, respectively. Figure 3
shows the effect of UAH and EAH on the expression of
GRO-α, RANTES, ICAM-1 and MMP-9, among other pro-
teins. EAH presented a significant (p < 0.05) reduction of
MMP-9 (38%), ICAM-1 (40%) and RANTES (47%); UAH
did not show a reduction (p > 0.05) in the expression of
Figure 1 Physicochemical properties of the main peptides found on unprocessed and extruded amaranth hydrolysates using PepDraw
tool, including amino acid sequence and structure, molecular mass, net charge, isoelectric point and hydrophobicity.
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with a reduction (p < 0.05) of 62% for both. Figure 4 indi-
cates the effect of UAH and EAH on the expression of
MCP-1, TfR, GM-CSF, FGF-19, and TNF-α, among other
growth factors related with atherosclerosis. UAH and EAH
showed a reduction (p < 0.05) of 35% and 42% for MCP-1;
48% and 61% for TfR; 59% and 63% for GM-CSF; 61% and
56% for FGF-19; 60% and 63% for TNF-α, respectively.
Figure 5 presents the effect of UAH and EAH on the
expression of TGF-α, resistin, and SDF-1α, among other
protein markers related with vascular pressure and ath-
erosclerosis. Both, UAH and EAH showed a reduction
(p < 0.05) of 100% on the expression of TGF-α. Resistin
and SDF-1α were only affected by the action of EAH
with a reduction of 62% and 41% (p < 0.05), respect-
ively. Other important molecules which were involvedin the atherosclerotic pathway, IL-11 and IL-1α, showed a
significant reduction (p < 0.05) in their expression after
24 h of cell treatment with UAH and EAH; EMMPRIN,
IL-1β and PTX-3 only showed a significant reduction
(p < 0.05) with EAH.
Extruded amaranth protein hydrolysate reduced the
expression of LOX-1, ICAM-1 and MMP-9 in LPS-induced
THP-1 macrophage-like human cells
Figure 6 shows the effect on THP-1 macrophage-like
cells from UAH and EAH on the expression of LOX-1
and ICAM-1, molecules involved in the atherosclerotic
pathway. LOX-1 expression was significantly reduced
(p < 0.05) (27%) at 1 mg/mL treatment with EAH,
while no reduction was observed at 1 mg/mL with UAH
(Figure 6A). The expression of ICAM-1 was significantly
Table 1 Protein markers involved on inflammatory and atherogenic pathways, their cell action and percent of
reduction by UAH and EAH1
Reduction (%)
Name Full name Cell action UAH EAH
TGF-α Transforming growth factor-α It is associated with vascular pressure and atherosclerosis [27] 100 100
IL-4 Interleukin-4 An increase in repair macrophages (M2) is coupled with
secretion of IL-10 and TGF-β [28]
69 100
IL-32α/β/γ Interleukin-32α/β/γ Pro-inflammatory cytokine. Responsible of NF-κB activation [29] 100 85
IL-22 Interleukin-22 It has a critical role in modulating local inflammation in certain
organs [30]
55 70
IGFBP-3 Insulin-like growth factor-binding protein-3 High levels are related with hypertension and atherosclerosis [31] 71 63
TNF-α Tumor Necrosis Factor-α It is expressed by the action of different stimulus, like LPS. It acts




Its function is as a white blood cell growth factor. It is part of the
immune/inflammatory cascade [33]
59 63
GRO-α Chemokine (C-X-C motif) ligand-1 It is a pro-inflammatory chemokine and is secreted by monocytes
in response to pro-inflammatory stimuli [34]
62 62
Resistin/ADSF Adipose tissue-specific secretory factor It is a pro-inflammatory cytokine [35] 14NS 62
TfR Transferrin receptor-1 Involved in the apoptosis of endothelial cells [36] 48 61
GDF-15 Growth differentiation factor 15 It has a role in regulating inflammatory pathway [37] NS 60
IL-11 Interleukin-11 It is rather pro-inflammatory in chronic inflammation [38] 66 57
FGF-19 Fibroblast growth factor-19 Inhibited the hepatic fatty acid synthesis [39] 61 56
MIF Macrophage migration inhibitory factor It encodes a lymphokine involved in cell-mediated immunity,
immunoregulation and inflammation [40]
46 53
IL-1α Interleukin-1 α It can induce the activation of nuclear factor-κB (NF-κB) [41] 41 53
IL-6 Interleukin-6 In chronic inflammation it is rather proinflammatory [42] 64 52
IL-12p70 Interleukin-12p70 It is a key YH-1 cytokine that drives inflammation in numerous
models of intestinal inflammation [43]
100 51
PDGF-AA Platelet-derived growth factor-AA It has been linked to atherosclerosis [44] 50 49
RANTES Chemokine(C-C motif) ligand-5 Involved in several clinical inflammatory conditions, such as
atherosclerosis [45]
33NS 47
EMMPRIN Extracellular-matrix metalloproteinase inducer It is involved in cytokines activation [46] NS 46
MCP-1 Monocyte-chemo attractant protein-1 It has been linked with chronic inflammatory diseases and
atherosclerosis [4,47]
35 42
SDF-1α Stromal derived cell factor-1α It can activate the nuclear factor-κB (NF-κB) [48] 19NS 41
ICAM-1 Intracellular Adhesion Molecule-1 Adhesion of monocytes is mediated by ICAM-1 [4] NS 40
IL-1β Interleukin-1 β Low and high levels produced inflammation, resulting in
tissue damage and tumor invasiveness [41]
NS 40
MMP-9 Matrix Metalloproteinase-9 Over-expression produces some disorders like inflammation
and atherosclerosis [17]
NS 38
PTX-3 Petraxin-3 Inflammatory marker thought to be more specific to
vascular [49]
77 NS
1Percent of reduction is relative to the positive control. UAH = unprocessed amaranth hydrolysate; EAH = extruded amaranth hydrolysate.
NS = not statistically different p <0.05.
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UAH did not affect its expression (Figure 6B). MCP-1 did
not show a significant difference with the control by west-
ern blot (Figure 7A). Figure 7B shows the effect of UAH
and EAH in the expression of MMP-9 which was signifi-
cantly (p < 0.05) reduced by 19% by EAH at 1 mg/mL,
while UAH had no effect.Extruded amaranth protein hydrolysate reduced the
expression of LOX-1, ICAM-1 and MMP-9 molecules in
LPS-induced THP-1 macrophage-like human cells by
immunocytochemical fluorescence confocal microscopy
Figure 8A and B show the total expression of LOX-1
after treatment of THP-1 cells with EAH. Six inde-
pendent fields of view from two independent cellular
Figure 2 Effect of unprocessed amaranth hydrolysate and extruded amaranth hydrolysate on human THP-1 macrophages-like cells
expression of interleukins related with inflammation and atherosclerosis process. Bars with different letter means they are statistically
different (p < 0.05) relative to the positive control (C+). All treatments contain lipopolysaccharide (LPS, 1 μg/mL) except negative control (C-)
treated with PBS-alone.
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The panel to the left (blue) represents the nuclei, the
panel in the middle (green) represents the response to the
primary antibody (either LOX-1, ICAM-1 or MMP-9),
and the third panel represents the merge of both. Panels
8A1 (nuclei), 8A2 (primary antibody) and 8A3 (merge)
show the results after the treatment with PBS alone (C-);
8A4, 8A5 and 8A6 show results after the treatment withFigure 3 Effect of unprocessed amaranth hydrolysate and extruded
expression of protein markers related with the process of inflamm
statistically different (p < 0.05) relative to the positive control (C+). All treatm
control (C-) treated with PBS-alone.PBS plus LPS (C+); while 8A7, 7A8 and 8A9 show the
results after the treatment with EAH at 1 mg/mL.
Figure 8B summarizes the intensity of LOX-1 after
24 h of treatment with EAH at 1 mg/mL. The inten-
sity of LOX-1 had a significant reduction (p < 0.05) of
58% after 24 h of treatment.
Figures 8C and D show the total expression of ICAM-1.
8C1, 8C2 and 8C3 show the treatment with PBS aloneamaranth hydrolysate on human THP-1 macrophages-like cells
ation and atherosclerosis. Bars with different letter means they are
ents contain lipopolysaccharide (LPS, 1 μg/mL) except negative
Figure 4 Effect of unprocessed amaranth hydrolysate and extruded amaranth hydrolysate on human THP-1 macrophages-like cells
expression of growth factors related with atherosclerosis. Bars with different letter means they are statistically different (p < 0.05) relative
to the positive control (C+). All treatments contain lipopolysaccharide (LPS, 1 μg/mL) except negative control (C-) treated with PBS-alone.
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with PBS plus LPS (C+); while 8C7, 8C8 and 8C9 show
only the treatment with EAH at 1 mg/mL. Figure 8D
shows the intensity of ICAM-1 after 24 h of treatment
with EAH at 1 mg/mL. The intensity of ICAM-1 had a
significant reduction (p < 0.05) of 52% after 24 h of treat-
ment. On the other hand Figures 8E and F show the total
expression of MMP-9. Panels 8E1, 8E2 and 8E3 show theFigure 5 Effect of unprocessed amaranth hydrolysate and extruded
expression of protein markers related with vascular pressure and a
different (p < 0.05) relative to the positive control (C+). All treatments conta
treated with PBS-alone.treatment with PBS alone (C-); 8E4, 8E5 and 8E6 show the
treatment with PBS plus LPS (C+); while 8E7, 8E8 and 8E9
show only the treatment with EAH at 1 mg/mL. Figure 8F
shows the intensity of MMP-9 after 24 h of treatment with
EAH at 1 mg/mL. The intensity of MMP-9 had a signifi-
cant reduction (p < 0.05) of 79% after 24 h of treatment.
Figure 9 indicates with red arrows the reducing ex-
pression of proteins by EAH treatment in a suggestedamaranth hydrolysate on human THP-1 macrophages-like cells
therosclerosis. Bars with different letter means they are statistically
in lipopolysaccharide (LPS, 1 μg/mL) except negative control (C-)
Figure 6 Effect of extruded amaranth hydrolysates on human
THP-1 macrophages-like cells expression of lectin-like oxidized
low-density lipoprotein receptor-1 (LOX-1) (A) and on the
expression of intracellular adhesion molecule-1 (ICAM-1)
(B). All experiments were performed in at least two independent
replicates. Different letter per column means statistically different (p < 0.05)
relative to the positive control (C+). All treatments contain
lipopolysaccharide (LPS, 1 μg/mL) except negative control (C-) treated
with PBS-alone.
Figure 7 Effect of extruded amaranth hydrolysates on human
THP-1 macrophages-like cells expression of monocyte-chemo
attractant protein-1 (MCP-1) (A) and on the expression of
matrix metalloproteinase-9 (MMP-9) (B). All experiments were
performed in at least two independent replicates. Different letter per
column means statistically different (p < 0.05) relative to the positive
control (C+). All treatments contain lipopolysaccharide (LPS, 1 μg/mL)
except negative control (C-) treated with PBS-alone.
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signaling pathway.
Discussion
Peptides with an active sequence related to the preven-
tion of atherosclerosis were found in the amaranth pro-
tein hydrolysates produced mimicking gastrointestinal
digestion after the extrusion of amaranth. In the present
study, we observed a reduction in the expression of pro-
teins linked to inflammation and atherosclerosis. IL-6 is
a molecule produced at the site of inflammation and when
chronic inflammation occurs, it acts as pro-inflammatory
marker [42]. Also, when protease-activated receptor (PAR)
is activated, it promotes the expression of IL-6, leading to
thrombosis [9]. Another molecule that was reduced by the
action of the amaranth treatment was chemokine CXC
motif ligand-1 (GRO-α), which is a pro-inflammatory
chemokine secreted by monocytes in response to pro-
inflammatory stimuli like LPS [34]. Other important
molecule involved in the activation of NF-κB pathwayis IL-1α [41], which was reduced by the action of the
treatment with both UAH and EAH. TNF-α plays an
important role in the inflammation/atherosclerosis
cascade, it acts as pro-inflammatory marker [32]. All of
these markers are very important in inflammation and
due to the strong relationship between inflammation
and atherosclerosis, these markers are also a target for
prevention.
The anti-atherosclerotic effect of EAH on LPS-induced
human THP-1 macrophages-like could be explained by
the capability of the peptides in amaranth protein hydroly-
sates to inhibit the activation of LOX-1, the principal re-
ceptor of ox-LDL in endothelial cells. Its expression is
elevated during initial and advanced atherosclerotic le-
sions as it is capable of binding products induced by in-
flammation [16,50]. The interaction of ox-LDL with its
Figure 8 Confocal laser scanning microscopy depicting two-dimensional immunocytochemical localization of LOX-1 (A), ICAM-1 (C),
MMP-9 (E) (green) and nuclei (blue) in human THP-1 macrophages after 24 h of treatment with extruded amaranth hydrolysates.
Quantification of total LOX-1 (B), ICAM-1 (D) and MMP-9 (F) intensity over their respective area sums over treatment time (μm2). (A1) Nuclei C-;
(A2) LOX-1 C-; (A3) Merge C-; (A4) Nuclei C+; (A5) LOX-1 C+; (A6) Merge C+; (A7) Nuclei treatment; (A8) LOX-1 treatment; (A9) Merge treatment.
(C1) Nuclei C-; (C2) ICAM-1 C-; (C3) Merge C-; (C4) Nuclei C+; (C5) ICAM-1 C+; (C6) Merge C+; (C7) Nuclei treatment; (C8) ICAM-1 treatment; (C9)
Merge treatment. (E1) Nuclei C-; (E2) MMP-9 C-; (E3) Merge C-; (E4) Nuclei C+; (E5) MMP-9 C+; (E6) Merge C+; (E7) Nuclei treatment; (E8) MMP-9
treatment; (E9) Merge treatment. Six independent fields of view from two independent cellular replicates were merged together per treatment
group. Means with different letters are significantly different from each other (n = 2, p < 0.05).
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endothelium via expression of both intracellular adhesion
molecule-1 and vascular adhesion molecule-1 (ICAM-1
and VCAM-1) [9]. The activation of adhesion molecules
results in the expression of MCP-1, promoting the mono-
cyte migration to the intima [13]. MCP-1 plays an import-
ant role in atherogenesis [47]. Using the protein expression
array, MCP-1 showed a reduction in its expression in cells
treated with both UAH and EAH, while western blot did
not detect differences for MCP-1, ELISA method was more
sensitive to detect differences in this response.
This molecule-receptor interaction, suggest a transform-
ation of the cells into foam cells [50]. Also, the upregula-
tion of LOX-1 may contribute to the plaque instability. Inthe present study we observed that at 1 mg/mL, EAH
inhibited the activation of LOX-1, ICAM-1 and MMP-9,
and a reduction in the expression of MCP-1. The reduc-
tion in the expression of these pro-atherosclerotic markers
could be explained by the reduction in pro-inflammatory
cytokines such as TNFα, IL-6, IL-1α, IL-1β and TGF-α
among others, which are stimuli that activated the expres-
sion of LOX-1, the principal receptor involved in athero-
sclerosis pathway [51]. All of these results were confirmed
using confocal microscopy, where the effects of the treat-
ment with EAH highly reduced the expression of MMP-9,
which is at the end stage of atherosclerosis [4]. The effect
observed in the principal markers are in agreement with
previous reports, where the positive effect on atherosclerosis
Figure 9 Potential mechanism of action of the EAH by reducing expression of proteins associated with LOX-1 signaling pathway. The
red arrows indicate the modulation obtained in this study, for each marker, due to EAH treatment. Numbers 1, 2, 3, 4 and 5 indicate the stages of
the atherosclerosis process.
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duced [4,8,21,51]. Previous studies showed that tryptic digest
of glutelins from amaranth possessed antihypertensive effect
and induced endothelial NO production, resulting in a
vasodilatation [21].
Figure 9 shows the suggested mechanism of action as-
sociated with LOX-1 signaling pathway. LOX-1 signaling
starts (1) by the action of different stimulus such as IL-6,
IL1α, TNF-α and LPS [51]. This stimulus produces inter-
action of the oxidized low density lipoprotein (ox-LDL)
with its receptor, LOX-1. This triggers reactions such asthe activation of adhesion molecules like ICAM-1, leading
into monocyte adhesion (2), resulting in foam cell forma-
tion (3), which increases the activity of MCP-1, producing
an increase on platelet adhesion (4), reactive oxygen spe-
cies (ROS) and increase on MMP-9 activity. All these
steps produce thrombus formation (5) with a possible rup-
ture and obstruction of the arterial blood flood [4]. Also,
the increase in ROS produce the activation of NF-κB, like-
wise some other markers such as IL-1α, SDF-α and IL-32/
α/β/γ also activate NF-κB [27,43]. NF-κB is a family of tran-
scription factors involved in many pathways including
Montoya-Rodríguez et al. Proteome Science 2014, 12:30 Page 10 of 13
http://www.proteomesci.com/content/12/1/30inflammation [26]. In our previous work [26] we found
peptides from amaranth hydrolysates with potential
antioxidant capacity and anti-inflammatory activity. Am-
aranth hydrolysates inhibited LPS-induced inflammation
in human and mouse macrophages by preventing activa-
tion of signaling via inhibition of the NF-κB subunits,
p-50 and p-65.Conclusion
Extruded amaranth protein hydrolysate inhibited LPS-
induced markers of atherosclerosis in human THP-1
macrophages-like by preventing the activation of LOX-
1 signaling. Furthermore, extrusion improved the anti-
atherosclerotic effect of amaranth protein hydrolysates
in THP-1 human cells, perhaps attributed to the for-
mation of bioactive peptides during the extrusion process.
This is the first study carried out with amaranth protein
hydrolysates in search for the potential prevention of car-
diovascular disease. Research is underway in our labora-
tory to test synthesized peptides of interest to evaluate
their direct effect, or synergistic effect, of all peptides
present in amaranth protein hydrolysates on markers of
atherosclerosis.Materials and methods
Material
The amaranth (Amaranthus hypochondriacus) grain was
grown and harvested during 2011 in Temoac, Morelos,
Mexico. Human acute monocytic leukemia cell line
(THP-1) and Roswell Park Memorial Institute-1640 media
(RPMI-1640, catalogue No. 10–2001), were purchased from
American Type Culture Collection (ATCC, Manassas, VA,
USA). Fetal bovine serum was purchased from Invitrogen
(Grand Island, NY). Streptomycin/penicillin and sodium
pyruvate were purchased from Cellgro (Manassas, VA,
USA). Lipopolysaccharide from Escherichia coli O55:B5 and
phorbol 12-myristate 13-acetate (PMA) were purchased
from Sigma-Aldrich (St. Louis MO). Lectin-like oxidized
low-density lipoprotein receptor-1 (LOX-1) rabbit poly-
clonal primary antibody (ab-69660) and matrix metallopro-
teinase-9 (MMP-9) rabbit monoclonal primary antibody
(ab-76003) were purchased from Abcam (Cambridge, MA,
USA). Monocyte chemoattractant protein-1 (MCP-1) rabbit
oligoclonal primary antibody (710002) and intracellular ad-
hesion molecule-1 (ICAM-1) rabbit oligoclonal primary
antibody (710278) were purchased from Invitrogen™
(Carlsbad, CA, USA). Glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA) and anti-mouse and
anti-rabbit IgG horseradish peroxidase conjugate second-
ary antibody were purchased from GE Healthcare. All
other chemicals were purchased from Sigma, unless
otherwise specified.Extrusion process
The extruded amaranth flour was obtained following the
procedure reported by Milán-Carrillo et al. [25]. The
amaranth grains (1 kg lots) were mixed with Ca(OH)2
(0.21 g/100 g amaranth) and conditioned with purified
water to reach a moisture content of 28%. Each lot was
packed in a polyethylene bag and stored at 4°C for 8 h.
Before extrusion, the grits were tempered at 25°C for
4 h. A single screw laboratory extruder Model 20 DN
(CW Brabender Instruments, Inc., NJ, USA) with a
19 mm screw-diameter; length to diameter 20:1; nominal
compression ratio 2:1; and die opening of 3 mm was
used. The inner barrel was grooved to ensure zero slip
at the wall. The temperature in the barrel was the same
for the three zones and the end zone was cooled by air.
A third zone, at the die barrel, was not cooled by air.
The feed rate was 30 rpm. Extrusion temperature (ET)
was defined as temperature at the die end of the barrel.
Extrusion operation conditions were: ET, 125°C and
screw speed (SS, 130 rpm). The extrudates were cooled,
equilibrated at environmental conditions (25°C, RH = 65%),
milled (UD Cyclone Sample Mill, UD Corp, Boulder, CO,
USA) to pass through an 80-US mesh (0.180 mm) screen,
packed in plastic bags, and stored at 4°C until their use.
Preparation of amaranth protein hydrolysates
The hydrolysis was carried out according to the method-
ology reported by Megías et al. [52] with some modifica-
tions as reported in Montoya-Rodriguez et al. [26]. Briefly,
amaranth flour (2.5 g) was suspended in water (1:20 w/v)
and a sequential enzyme digestion was carried out with
pepsin [EC 3.4.23.1, 662 units/mg; enzyme/substrate, 1:20
(w/w); pH 2.0] and pancreatin [8x USP (a mixture of
several digestive enzymes produced by the exocrine
cells of the porcine pancreas, EC 232-468-9, Sigma-
Aldrich P7545); enzyme/substrate, 1:20 (w/w); pH 7.5]
at 37°C for 120 min for each enzyme. The final hydrolysis
was stopped by heating at 75°C for 20 min, and the result-
ing hydrolysate was centrifuged at 20,000 g for 15 min at
4°C. The hydrolysates were desalted using 500 Da cellulose
acetate membranes (The Nest Group, Inc.), and freeze
dried in a Labconco (Kansas, MO) Freeze Dryer 4.5.
Cell culture and treatments
THP-1 is a human monocytic-derived cell line [53],
which matures into human macrophage-like adherent
cells following stimulation with phorbol 12-myristate
13-acetate (PMA) [54]. THP-1 was cultured using Ros-
well Park Memorial Institute-1640 media (RPMI 1640)
(ATCC) containing 10% fetal bovine serum (FBS), 1%
penicillin-streptomycin, 1% sodium pyruvate and 50 μM
β-mercaptoethanol (to prevent crosslinking of Fc recep-
tors on the cell by the antibody in serum and therefore
avoiding damaging cell function), and incubated at 37°C
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was added at a concentration of 162 nM to promote differ-
entiation of THP-1 cells into macrophages as previously de-
scribed by Furundzija et al. [55], with some modifications.
Macrophage differentiation was allowed for 48 h and it was
determined by cell morphology and total adhesion to the
plate. Human THP-1 macrophages-like were seeded at a
density of 1,000,000 cells per 2-mL in a 6-well plate and
after complete adhesion, treated with sterile-filtered UAH
and EAH at a concentration of 1 mg/mL for 24 h. This
concentration was selected based on our preliminary data
of the concentration needed to inhibit 50% of the anti-
inflammatory pathway (IC50) [26]. To stimulate inflamma-
tion, cells were treated with 1 μg/mL LPS dissolved in
growth medium. Cells treated with PBS and LPS served as
positive control while cells treated with PBS-alone served
as negative control. After 24 h of treatment, growth
medium was aliquot and immediately frozen at −20°C until
use.
Cell viability
Cell viability of THP-1 human macrophages-like was per-
formed following the method reported in our previous re-
search [26]. The viability of the cells was not affected with
the highest treatment concentration (1 mg/mL) used in
the present study.
Proteins/cytokines array
The expression profile of atherogenic-related proteins
was performed and analyzed using a Human XL Cyto-
kine Array (Ary022, R&D Systems, MN) according to
the manufacturer instructions. Briefly, THP-1 cells were
seeded at a density of 1 × 106 cells in a 75 cm2 canted
neck flask, with PMA at 162 nM (to promote differenti-
ation) for 24 h at 37°C in 5% CO2/95% air. After 24 h,
cells were washed twice with PBS to remove the PMA
and treated with PBS, UAH and EAH (1 mg/mL) and
LPS for 24 h. Cells treated with PBS alone was used as a
negative control. After 24 h of treatment, cells were har-
vested using lysis buffer reagent and the expression of
proteins in the cell lysates was determined following the
manufacturer’s protocol.
Western blot analysis of LOX-1, ICAM-1 and MMP-9
Cell lysates obtained in a similar manner as for the
protein array were used for this study. Protein concen-
tration of the whole cell lysates was determined by
protein DC assay (Biorad, Hercules, CA) and equal
volume of the lysates and Laemmli buffer containing
5% β-mercaptoethanol was boiled for 5 min. Cell ly-
sates were immediately frozen until used for western
blotting to measure expression of pro-atherosclerosis
markers such as LOX-1, ICAM-1 and MMP-9. Equal
amount of protein (25 μg) from whole cell lysates wasloaded in 4–20% gradient SDS-polyacrylamide gels
(Bio-Rad Laboratories, Inc.). The separated proteins were
transferred onto PVDF membranes (GE Healthcare
Biosciences) and blocked with 5% nonfat dry milk in
0.1% Tris-buffered saline Tween 20 (TBST) for 1 h at
4°C. The membranes were washed with 0.1% TBST and
incubated with either LOX-1 rabbit polyclonal primary
antibody, ICAM-1 rabbit polyclonal primary antibody
or MMP-9 rabbit monoclonal primary antibody over-
night at 4°C. The membranes were washed again with
TBST (5x, 5 min each) and incubated with anti-rabbit
IgG horseradish peroxidase conjugate secondary anti-
body (GE Healthcare, Piscataway, NJ) for 1 h at room
temperature. After incubation and repeated washing, the
membranes were prepared for detection using a 1:1 mix-
ture of chemiluminescent reagents A (luminol solution)
and B (peroxide solution) (GE Healthcare, Piscataway,
NJ). The membrane pictures were taken on a GelLogic
4000 Pro Imaging System (Carestream Health, Inc.,
Rochester, NY). The relative amount of each target pro-
tein was normalized to GAPDH. All western blot proce-
dures were determined in at least three independent trials.
Each treatment was performed in at least a triplicate to
confirm reproducibility.
Immunocytochemical fluorescence confocal microscopy
Briefly, 20, 000 THP-1 cells were seeded in 300 μL of
phenol red-free RPMI-1640® medium (Life Technologies)
with PMA at 162 nM (to promote differentiation) in ibi-
Treat microscopy chambers (ibidi) for 48 h at 37°C in
5% CO2/95% air. After 48 h of differentiation, cells were
washed twice with PBS to remove all the PMA and
treated with EAH at 1 mg/mL for 24 h. Cells were
washed three times with PBS and fixed with 4% para-
formaldehyde aqueous solution (Electron Microscopy
Sciences) for 30 min at room temperature, washed
three times 5 min each with PBS, and permeabilized
with 0.1% Triton X-100 in PBS for 15 min at room
temperature. Cells were washed once with PBS and incu-
bated with ultra-cold HPLC-grade methanol for 15 min
at −20°C. Methanol was removed and replaced with PBS
and incubated for 30 min at room temperature. Cells were
blocked with Image-iT FX Signal Enhancer (Life Tech-
nologies) for 30 min at room temperature, washed once
with PBS and incubated with either LOX-1 (5 μg/mL),
ICAM-1 (1:250) or MMP-9 (1:250) monoclonal primary
antibody for 5 h at 37°C. After incubation, cells were
washed three times 5 min each with PBS and incubated
with Alexa Fluor 488 Goat Anti-rabbit (Life Technologies)
secondary antibody (1:200) for 3 h at 37°C. Cells were
washed three times with PBS and cured with ProLong
gold antifade reagent with DAPI (Life Technologies) for
24 h at 25°C in the dark. The chamber was stored at 4°C
until further use. The cells were visualized using a Carl
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AG, Germany) with 63x oil immersion objective. Total in-
tensities and area sums were quantified with AxioVision
Rel 4.8 (Carl Zeiss).Statistical analysis
Statistical analyses were conducted using the proc GLM
procedures of SAS version 9.3 (SAS Inst. Inc., Cary,
NC). Group mean comparisons were conducted using
LSD means and were considered to be significant at p < 0.05
based on minimum significant differences from one-way
analysis of variance (ANOVA) with alpha≤ 0.05. All analyses
were performed in at least three independent replicates.
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